This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.

The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wherein R.sub.1 is C.sub.1-C.sub.4 alkyl, hydroxy, or C.sub.1-C.sub.4 alkoxy; Z is NH, NCH.sub.3, O, S, or CH.sub.2; Y is NH, O, or CH.sub.2 with the proviso that Y and Z are not the same; R.sub.2 is H, halo, NH.sub.2, C.sub.1-C.sub.4 alkyl, hydroxy, or C.sub.1-C.sub.4 alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m+n=an integer ranging from 2-9; and R.sub.3 is H, halo, NH.sub.2, C.sub.1-C.sub.4 alkyl, hydroxy, or C.sub.1-C.sub.4 alkoxy. ##STR00001##

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

The present disclosure discloses a composition comprising (2Z, 3E)-6-Bromoindirubin-3-oxime or its derivative for use in treatment of neurodevelopmental and of neurodegenerative disorders. The disclosure further relates to a method for correcting the behavioural deficits in a subject with neurodevelopmental and neurodegenerative disorders comprising administering the subject with a therapeutically effective amount of (2Z, 3E)-6-Bromoindirubin-3-oxime or its derivative.

The present disclosure discloses a composition comprising (2Z, 3E)-6-Bromoindirubin-3-oxime or its derivative for use in treatment of neurodevelopmental and of neurodegenerative disorders. The disclosure further relates to a method for correcting the behavioural deficits in a subject with neurodevelopmental and neurodegenerative disorders comprising administering the subject with a therapeutically effective amount of (2Z, 3E)-6-Bromoindirubin-3-oxime or its derivative.

The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 (mGluR2). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which mGluR2 subtype of metabotropic receptors is involved.

Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.

The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.

The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 (mGluR2). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which mGluR2 subtype of metabotropic receptors is involved.

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.